心血管薬による社会的利益の増大
Marcello Tonelli1, Sharon Straus2
1Department of Medicine, University of Calgary, Canada (M.T.).
Circulation
|November 21, 2022
まとめ
SGLT2阻害剤やGLP-1アゴニストのような慢性疾患に対する新しい治療法は 改善された結果をもたらします この本では 社会的利益の最大化,価値の確保,すべての患者に対する 公平なアクセスを促進するための 5つの原則を概説しています
科学分野:
- 薬理学と治療法
- 健康 経済
- 公衆衛生政策
背景:
- 非伝染性慢性疾患 (NCD) の治療には,ナトリウム・グルコース・コトランスポーター-2 阻害剤 (SGLT2i),グルカゴン類ペプチド1アゴニスト (GLP-1a),アンジオテンシン受容体・ネプリリン阻害剤 (ARNI),フィネレンロンなど,いくつかの革新的な治療法があります.
- これらの新薬は,既存の治療法に統合されたときに臨床的に重要な結果が改善され,その使用の指示が拡大しています.
- 現在の薬物規制の複雑さとコストは,社会がこれらの進歩から最大限の利益を得られるようにするための大きな課題です.
研究 の 目的:
- 革新的なNCD治療による社会的利益を最大化するという課題に取り組むこと.
- 新しい治療法の最適化のための5つの基本原則に基づく枠組みを提案する.
- 高所得国の利害関係者を指導し,低所得国と中所得国に広く適用可能な原則を提供する.
主な方法:
- 社会的利益のための主要な原則を概説する議論に基づいたプライマーです.
- ケーススタディとして,ナトリウム・グルコース・コトランスポーター-2 阻害剤 (SGLT2i) に焦点を当てる.
- ARNI,フィネレノンのような他の健康製品と将来のイノベーションに適用できるフレームワーク
主要な成果:
- 利益の最大化,害の最小化,利用率の最適化,価格の相応性の向上, 公平なアクセスを確保するという5つの原則を特定しました.
- これらの原則がSGLT2iを超えて他の新しいNCD治療法にも広く適用できることを強調した.
- 高所得国や低所得から中所得国を含む多様な経済環境における利害関係者にとって重要であることを強調した.
結論:
- 戦略的,原則に基づくアプローチは,革新的なNCD治療の完全な社会的価値を実現するために不可欠です.
- SGLT2i,GLP-1a,ARNI,およびフィネレノンなどの新薬の普及とアクセシビリティを最適化するには,経済と公平性の要因を慎重に考慮する必要があります.
- 提案された5つの原則は,先進的な治療法を世界的に医療システムに統合する際の複雑さを把握するための堅固な枠組みを提供します.
関連する概念動画
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
3.1K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
3.1K
01:17Exercise and Cardiac Output
1.2K
Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be...
Sustained exercise increases the muscles' oxygen demand, which can be...
1.2K
01:26Atherosclerosis III: Management
19
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
19
01:20Exercise and Cardiovascular Response
1.0K
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
1.0K
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
483
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
483